StreetAlpha.app
Home › Stocks › MTRI

InMed Pharmaceuticals Inc. (MTRI)

Healthcare
$17.50
▼ −11.93%
LAST CLOSE · NOV 17

InMed Pharmaceuticals develops small molecule drug candidates for Alzheimer's, eye disease and a skin condition. It last closed at $17.50 on Nov 17, down 11.93% on the day. MTRI reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $31.00 (+77.1% from the last close), with a high of $33.00 and a low of $30.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $2.7M, the largest $2.7M.

AI Auto Pilots
Is MTRI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$13.2M
EPS (diluted)
−$3.10
Valuation
Market cap
$96.1M
5.5M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$1.1M
At Sep 30
Shareholder equity
−$1.2M
Shares outstanding
5.5M
At Oct 30
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $1.1M$1.1MFY2022FY2023: $4.1M$4.1MFY2023FY2024: $4.6M$4.6MFY2024FY2025: $4.9M$4.9MFY2025

From MTRI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 10
2027 · Time not announced
Consensus EPS forecast
-$0.54
 
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on MTRI in the past 90 days
Average 12-month target
$31.00
▲ 77.1% upside

Based on 3 analysts who set a price target on MTRI in the past 90 days. The average target is $31.00, with a high of $33.00 and a low of $30.00, compared with the last close of $17.50.

Low $30.00Avg $31.00High $33.00
Blue marker: last close $17.50
Highest target$33.00
Average target$31.00
Lowest target$30.00
Latest rating changes
WedbushInitiated
Nov 13Buy$33
JefferiesInitiated
Nov 10Buy$30
StifelInitiated
Nov 10Buy$30
DateFirmActionRatingPrice target
Nov 13WedbushInitiatedBuy$33
Nov 10JefferiesInitiatedBuy$30
Nov 10StifelInitiatedBuy$30
Loading…

Whale Options Flow

90D

No whale options trades in MTRI in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$2.7M
Largest print
$2.7M
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MTRI is in one of them and how their past MTRI trades turned out.

MTRI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MTRI in an article yet. Here's the latest on the wider market.

About InMed Pharmaceuticals

InMed Pharmaceuticals is a drug development company based in Vancouver, Canada. It develops small molecule drug candidates that act on the CB1 and CB2 receptors of the endocannabinoid system, which is found throughout the body. Its pipeline targets Alzheimer's disease, dry macular degeneration (AMD) and epidermolysis bullosa, a skin condition. Most of its programs are at the preclinical stage, while its cannabinol cream has completed a Phase 2 trial in epidermolysis bullosa.

Headquarters
Vancouver